Company intelligence / Profile preview

Future Cardia

Houston, Texas, United Statesfuturecardia.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Future Cardia has developed an under-the-skin insertable cardiac monitor for long-term heart failure and arrhythmia management. As of late 2024, the device had been implanted in at least 39 patients for data collection. The first-in-human clinical trial ("Voice Of the Heart") began in December 2023 and was actively recruiting as of mid–2025. No commercial sales or pivotal trial results have been reported yet.

Therapeutic areas: Cardiovascular
Modalities: Device (specifically insertable cardiac monitor)Digital health platform (AI-enabled monitoring)
Industry: Physiological Monitoring

Partnerships

Stanford StartX accelerator/supporter; no major pharma or medtech partnerships disclosed yet

Beyond the preview

Go deeper on Future Cardia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Future Cardia.

Explore the full profile